Classes — Torrey Pines Investment
Summary
Virioms pipeline includes: Elpida\xae (elsulfavirine), the best-in-class NNRTI that obtained first market authorization in 2017; extended release weekly oral formulations; and long-acting injectable therapy and prophylaxis. In a prospective trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary HD-MAP technology platform, which uses an ultra-high density array of projections invisible to the naked human eye applied to the skin to rapidly deliver vaccine to the abundant immune cells immediately below the skin surface. Vaxxas uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation easing the resource and logistics burden of maintaining the cold chain. Vaxxas is targeting initial applications in infectious disease and oncology.Context Therapeutics Inc., is a womens oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers.